Slides
Page 1
Capital Markets Day November 4, 2026 Melbourne, Australia ASX: TLX | NASDAQ: TLX Radiopharmaceutical manufacturing suite at TMS North Melbourne.
Page 2
This presentation should be read together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website. The information contained in this presentation is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this presentation are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this presentation, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in this presentation. This presentation may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Telix’s actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. This presentation also contains estimates and other statistical data made by independent parties and by Telix relating to market size and other data about its industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data and estimates. In addition, projections, assumptions and estimates of Telix’s future performance and the future performance of the markets in which it operates are necessarily subject to a high degree of uncertainty and risk. Use of Non-IFRS Measures. Telix’s results are reported under International Financial Reporting Standards (IFRS). This announcement includes various non-IFRS financial information to reflect its underlying performance, which have not been subject to audit or review. These non-IFRS measures include Adjusted EBITDA, which represents net earnings attributable to the Group excluding finance costs, income tax expense, depreciation and amortization, remeasurement of provisions, other income and expenses. As required by SEC rules, we have provided reconciliations of these non-IFRS financial measures to the most directly comparable IFRS measures, which for Adjusted EBITDA, is Profit/(loss) before income tax. The Group believes that these non-IFRS measures, which are not considered to be a substitute for or superior to IFRS measures, provide stakeholders with additional useful information on the underlying trends, performance and position of the Group and are consistent with how business performance is measured internally. The non-IFRS measures are not defined by IFRS and therefore may not be directly comparable with other companies’ alternative performance measures. Telix’s first generation PSMA-PET imaging product, gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix®), has been approved in multiple markets globally. Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection) has been approved by the U.S. Food and Drug Administration (FDA). Telix’s glioma imaging agent, floretyrosine F 18, marketed under the brand name Pixclara®, is also approved by the FDA. Telix’s osteomyelitis (bone infection) imaging agent, technetium-99m (99mTc) besilesomab (marketed under the brand name Scintimun®) is approved in 32 European countries and Mexico. Telix’s miniaturized surgical gamma probe, SENSEI®, for minimally invasive and robotic-assisted surgery, is registered with the FDA for use in the U.S. and has attained a Conformité Européenne (CE) Mark for use in the EEA. Registrations vary country to country. Refer to your local approved label or regulatory authority status for full information. No other Telix drug or device has received marketing authorization in any jurisdiction. Any other Telix drug or device that is discussed in this presentation, including Zircaix and Pixlumi, is investigational or under development and not approved by any regulatory authority. The efficacy or safety profile of any unapproved drug or device has not been determined by any regulatory authority. In addition, Zircaix and Pixlumi brand names and launch are subject to final regulatory approval. All trademarks and trade names referenced in this presentation are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties. ©2026 Telix Pharmaceuticals Limited. All rights reserved. 2 Forward looking statement
Page 3
Telix management Dr. Christian Behrenbruch Dr. David N. Cade, MD 3 Mr. Darren Smith Managing Director and Group CEO Group Chief Financial Officer Group Chief Medical Officer
Page 4
Key Opinion Leaders 4 Presenters are independent experts not employed by Telix but have been paid fair market value for their time. Views expressed are speakers’ own. Any presenter’s response during Q&A has not been reviewed in advance by Telix. Prof. Louise Emmett Director of Theranostics and Nuclear Medicine St Vincent’s Hospital, Sydney, Australia Prof. Munir Ghesani Nuclear Medicine Physician, Professor of Radiology Icahn School of Medicine Mount Sinai and Chief Medical Officer at United Theranostics, USA Dr. Philip Dundee Urological Surgeon, Director Robotic Surgery Fellowship Program, Royal Melbourne Hospital, Australia Prof. Andrew Scott Professor of Medicine, University of Melbourne, La Trobe University, Head of Tumour Targeting Laboratory Olivia Newton-John Cancer Research Institute, Australia
Page 5
Strategy & overview Dr. Christian Behrenbruch Managing Director and Group CEO
Page 6
6 Telix at a glance A diversified, vertically integrated radiopharma company 3 FDA-approved products Illuccix® Gozellix® Pixclara® 22 countries Illuccix® commercially available 45 manufacturing and distribution sites globally US$950M-$970M (AUD $1.36-1.39B) revenue guidance Integrated theranostic approach: See It. Treat It. High-value therapeutics pipeline R&D platform for new molecular entities Precision Medicine portfolio Specialist commercial organization Vertically integrated manufacturing and supply As of October 30, 2026. 1. ASX release October 21, 2026. Our purpose: We help people with cancer and rare diseases live longer, better quality lives FY20261
Page 7
Radiopharmaceuticals: a rapidly expanding market Source: MEDraysIntell 2025 Nuclear Medicine Report. Industry forecasts, not Telix guidance. Notes: Diagnostics includes SPECT tracers (including 111In, 123I and 201Tl), PET includes 68Ga generators. 1. Exhibit 16, William Blair: Radiopharmaceuticals- 5th Edition. 2. Exhibit 11, William Blair: Radiopharmaceuticals- 5th Edition. Global nuclear medicine market growth 2024 2030 2034 11 27 41 Therapeutics 2024–2034, USD billions CAGR (10yr): 26% Therapeutics Over 100 therapeutic targets under investigation1 41 Lu-177 candidates 34 Ac-225 candidates 25 Pb-212 candidates 16 At-211 candidates ~50 radiopharmaceutical companies with a focus on therapeutics2 Continued global demand for imaging agents CAGR (10yr): Therapeutics: 26% Diagnostics: 5% ~US$3B 2024 Diagnostics (incl. PET and SPECT tracers) ~US$27B 2034 7
Page 8
Commercial expansion, novel therapies and integrated supply underpin our growth strategy Three growth engines creating long-term value Scaled commercial business Extend market-leading precision medicine commercial position through product innovation, diversification and global expansion. Therapeutic and precision medicine pipeline Advance multiple products and therapies to market, expanding patient access to transformative diagnostics and therapeutics. Best-in-class manufacturing & supply Expand vertically integrated global supply chain to enhance capacity, control and scalability. 1 2 3 8
Page 9
Three FDA approved precision medicine products fuel our commercial engine 9 • Clinical differentiation, proven track record, year over year volume growth • Launched in 22 countries1 • NDA under review by NMPA in China2 • Registration enabling study completed enrollment in Japan3 • First FDA-approved FET-PET imaging drug for glioma4 • Included in National Comprehensive Cancer Network (NCCN®) guidelines • Inclusion in International guidelines: EANM/EANO/RAN O/SNMMI FDA APPROVED FDA APPROVED FDA AP P RO V E D Scaled commercial business1 NDA = New Drug Application. NMPA = National Medical Products Administration. 1. Telix ASX disclosure April 6, 2026. 2. Telix ASX disclosure January 20, 2026. 3. Telix media release July 17, 2026. Japan Registry of Clinical Trials identifier: JRCT2031250473. 4. Telix ASX disclosure September 14, 2026.
Page 10
Expanding addressable market for our commercial business and near-term commercial products Commercial Products Near-Commercial Product U.S. TAM Scans / patients $ Illuccix/Gozellix ~670,000 scans ~$2.7B Pixclara ~21,200 scans ~$106M Zircaix ~116,320 scans ~$600M ITM-111 ~13,800 patients ~$1.7B Potential to add three-high value commercial products in 2027 Diagnostic Prostate cancer Diagnostic Brain cancer (Glioma) Diagnostic Kidney cancer Therapeutic Neuroendocrine tumors (GEP-NETs) BiPASS ~821,000 scans ~$3.3B Diagnostic Prostate cancer (Pre-Biopsy) ~$300M+2 1 Source: Datamonitor, Clarivate, internal estimates. Total Addressable Market (TAM) for Precision Medicine uses $4,000/scan for modelling purposes. Therapeutics candidates are using $250,000/treatment based on commercial benchmarks/Datamonitor. These price points do not reflect the actual price charged or the price that Telix will charge in the future. Intended for investor audience only. The FDA has approved Illuccix for use in initial staging, BCR, and RLT selection. The FDA has approved Gozellix for use in initial staging and BCR. Not intended to advertise or promote any other product or indication. BiPASS has not been accepted by the FDA to diagnose, treat, cure, or prevent any disease. Brand names subject to regulatory approval. 2. Potential for baseline FET PET scanning. 1. This asset is included subject to closing of the ITM transaction, which remains subject to Telix Shareholder approval, regulatory approvals and other customary closing conditions. Scaled commercial business 10
Page 11
Late-stage therapeutic pipeline transformational to Telix’s growth 11 TAM Source: Datamonitor, Clarivate, internal estimates. Total Addressable Market (TAM) for Precision Medicine uses $4,000/scan for modelling purposes. Therapeutics candidates are using $250,000/treatment based on commercial benchmarks/Datamonitor. These price points do not reflect the actual price charged or the price that Telix will charge in the future. TLX591-Tx ~$5.6B ~22,460 Patients TLX597-Tx ~$4.2B ~16,800 Patients TLX101-Tx ~$1.2B ~8,100 Patients TLX250-Tx ~$1.1B ~4,700 Patients Transformational therapeutic opportunities Higher-margin product launches Prostate cancer (mAPMR) Prostate cancer (mAPMN/S) Brain cancer (Glioblastoma) Kidney cancer Late -stage pipeline Late-stage therapeutics U.S. TAM 2 Status Phase 3 Phase 2 Phase 3 Phase 2/3 Interim futility analysis Optimal-PSMA data readout Enrollment progression Enrollment progression Upcoming milestones
Page 12
Vertically integrated manufacturing drives scale and value Supply-chain control matters in a sector defined by time-critical delivery, specialist infrastructure, complex regulation and limited suppliers From secure supply to timely and reliable patient access Less reliance on third parties Greater ability to build redundancy. More streamlined technology transfer between discovery, development and manufacturing. COGS advantage and process optimization. Efficient dose calibration and lower distribution costs. Reduced regulatory risk and a seamless CMC package. Lower exposure to third-party quality and reliability risks. Seamless transition from development to commercial operations. Isotope and cGMP infrastructure for clinical and commercial scale-up. Closer collaboration across isotope scientists, radiochemists, biologists and chemists. Refined processes to move discoveries toward clinical use. 3 Best -in -class manufacturing Supply security Speed Economics Scalability Risk mitigation Faster innovation 12
Page 13
Specialized radiopharma supply chain Building in-house capabilities across critical stages of the value chain Best -in -class manufacturing3 1. The transaction with ITM is expected to close in FY2026 subject to Telix Shareholder approval, regulatory approvals, and other customary closing conditions. Radioisotope supply Isotopes Irradiation and purification Targeting molecules Antibody or small molecule Chelator conjugate Cold kit Non-radioactive Radiolabelled drug product Radioactive product Unit dose Quality control and release Last-mile delivery Distribution to point of care Telix capabilities • Isotope production • Bioconjugation / isotope processing • Seneffe: GMP manufacturing, QC, secondary packaging • Yokohama: Clinical manufacturing • Sacramento: Clinical doses/ process development • North Melbourne: Hotlab, dosimetry • Radiolabelling, dispensing, distribution network 13 + 1 • Isotope manufacturing and distribution network
Page 14
In-house radioisotope production capabilities Supports current commercial and late-stage portfolio, plus next generation therapeutics 14 3 ARTMS – QIS® Technology • Radiometal production technology deployed on all Telix Group cyclotrons and global partner network • Large scale regional 68Ga production supporting future 68Ga-PSMA-11 demand including BiPASS • High volume 89Zr production ready for Zircaix commercial launch ITM1 – Global leader in Lu-177 • World leader in 177Lu production for quality and scalability • Capacity to supply commercial scale TLX591-Tx, TLX597-Tx, TLX250-Tx, ITM-11, or any other 177Lu therapy • Largest stockpile of starting material and most secure irradiation sources in the industry Control over next generation alphas • Validated Telix 212Pb generator, with potential to scale to commercial levels • Partnership with IBA/Framatome (Ekalia) for 211At in U.S. • 225Ac internal production technology through ITM x Actineer JV and co- development agreement with EZAG Best -in -class manufacturing 1. The transaction with ITM is expected to close in FY2026 subject to Telix Shareholder approval, regulatory approvals, and other customary closing conditions.
Page 15
Scaled globally, positioned for long-term value Global manufacturing and supply chain footprint 15 Telix Manufacturing Solutions site Strategic partner Seneffe, Belgium Yokohama, Japan Melbourne, Australia
Page 16
Transaction reinforces Telix’s growth strategy High value therapeutics pipeline Vertically integrated manufacturing / supply chain Specialist commercial organization R&D platform for new molecular entities Precision Medicine portfolio Accelerates entry into therapeutic commercial infrastructure & supply chain Enhanced development capabilities Novel product and life-cycle management opportunities Adds commercial depth and expertise Value creation from therapeutic radioisotopes leadership ✓ ✓✓ ✓✓ The combination of ITM + Telix enhances our ability to compete 16 1 1. The transaction with ITM is expected to close in FY2026 subject to Telix Shareholder approval, regulatory approvals, and other customary closing conditions. Telix & ITM
Page 17
Telix + ITM positioned to service growing commercial and clinical demand Industry forecasts are not Telix guidance. Development-asset counts are industry-wide, not Telix’s pipeline. 1. Advancy research & analysis, Commercial Vendor Due Diligence, February 2026. 2. William Blair Equity Research 2026. INDUSTRY ASSETS IN DEVELOPMENT² ¹⁷⁷Lu 41 assets in development Plus two therapies at commercial stage ²²⁵Ac 34 assets in development Second most-used isotope in trials, behind ¹⁷⁷Lu Radioisotope markets forecast to compound at ~30% p.a. through 20351 177Lu total market (US$B)1 Growth to $2.1B risk adjusted by 2035 225Ac total market (US$B)1 Growth to $1.4B risk adjusted by 2035 $0.5 B $2.1 B $0.0 $0.5 $1.0 $1.5 $2.0 $2.5 2025 2035 $0.1 B $1.4 B 0.0 0.5 1.0 1.5 2.0 2.5 2025 2035 45% CAGR 23% CAGRUS$B US$B TELIX & ITM Security of supply increasingly valuable as more assets progress to commercialization The transaction with ITM is expected to close in FY2026 subject to Telix Shareholder approval, regulatory approvals, and other customary closing conditions.
Page 18
Building a radiopharmaceutical powerhouse Positioned for leadership in a fast-growing segment of oncology Why invest now? • Ensures Telix has the critical infrastructure, supply and capacity to meet demand for commercial products. Attract world-class talent • An integrated R&D, manufacturing and commercial platform positions Telix to attract and retain specialist talent. Partner of choice for the next generation • R&D focused on novel and next-generation targets positions Telix as a strategic partner of choice for big pharma, academic researchers and other innovators. Secure supply and protect launches Capability Big pharma Consolidated Specialty radiopharma Consolidated Telix + ITM Therapeutic: Lutetium ✓ ✓ ✓ Therapeutic: Actinium ✓ ✕ ✓ Therapeutic: Terbium ✕ ✕ ✓ Therapeutic: Iodine ✕ ✕ ✓ Targeting modality: Peptide ✓ ✓ ✓ Targeting modality: Antibody ✓ ✕ ✓ Targeting modality: Small molecule ✓ ✓ ✓ Commercial diagnostics ✓ ✓ ✓ Isotope supply: Lutetium ✕ ✓ ✓ Isotope supply: Actinium ✓ ✕ ✓ Source: Public filings, Wall Street research, clinicaltrials.gov, FactSet, and ITM Management as of October 2026. 18 TELIX & ITM The transaction with ITM is expected to close in FY2026 subject to Telix Shareholder approval, regulatory approvals, and other customary closing conditions.
Page 19
19 JV TMS Sacramento Telix planned cyclotron installation at RLS locations 3x manufacturing sites & 2x cyclotrons in BE Global HQ & 2x manufacturing sites in DE TMS Yokohama Cyclotron facility JV US HQ US HQ Global HQ & TMS North Melbourne Network covering >85% of the U.S. market The transaction with ITM is expected to close in FY2026 subject to Telix Shareholder approval, regulatory approvals, and other customary closing conditions. Creating a fully integrated global radiopharma leader Strong foundation and geographic footprint to support global therapeutic launches Telix & ITM
Page 20
Dr. David N. Cade Group Chief Medical Officer Pipeline
Page 21
Late-stage and “next generation” therapeutic assets 21 Pixlumi, Zircaix brand names subject to regulatory approval. PSMA: Prostate-specific membrane antigen. CAIX: Carbonic anhydrase IX. LAT1: L-Type amino acid transporter 1. CD66: Cluster of differentiation 66. PDGFRα: Platelet-derived growth factor receptor alpha. mAb: Monoclonal antibody. SM: Small molecule. FAP: Fibroblast activation protein.
Page 22
Transformative portfolio expansion across early and late-stage assets 22 • Co-development and co-commercialization agreement to develop candidates focused on alpha therapies • 4 initial therapeutic programs, with option for 4 additional programs • Up to $2.1B USD developmental and commercial milestone payments plus royalties (4 initial programs), with option for 4 additional programs 1. Telix ASX disclosure April 13, 2026. 2. Telix ASX disclosure September 21, 2026. The transaction with ITM is expected to close in FY2026 subject to Telix Shareholder approval, regulatory approvals, and other customary closing conditions. • Adds a complementary therapeutic franchise with multiple pathways for growth • ITM-11 Phase 3 expansion programs create meaningful commercial opportunities • Late-stage pipeline supports label expansion into G2/G3 GEP-NETs, plus NETs of lung or thymus origin • Globally scaled commercial-grade supplier - world’s largest supplier of 177Lu 1 2
Page 23
Prostate cancer 68Ga PSMA-11 in practice Dr. Munir Ghesani Chief Medical Officer United Theranostics
Page 24
68Ga PSMA-11 has set a high bar in staging and BCR 24 BCR: biochemical recurrence. 1. Hofman, Lancet 2020; Hope, JAMA Oncol 2021; Fendler, JAMA Oncol 2019; Hope, J Nucl Med 2019; Esperto, Cancers 2026. 2. ClinicalTrials.gov ID: NCT05847348. Data on file. 3. NCCN 2025; AUA/ASTRO/SUO 2024; EAU; Telix 2021, 2023 and 2025. High-risk, pre-treatment staging1 (proPSMA randomized trial, n = 295 with follow up) Metric CT + bone scan 68Ga PSMA-11 PET/CT Accuracy 65% (60–69) 92% (88–95) Sensitivity 38% (24–52) 85% (74–96) Specificity 91% (85–97) 98% (95–100) Management change 15% 28% Equivocal findings 23% 7% Radiation exposure 19.2 mSv 8.4 mSv Baseline PSA (ng/mL) PPV (95% CI) ≥ 5.0 100.0% (78.5%, 100.0%) < 5.0 to 2.0 100.0% (67.6%, 100.0%) < 2.0 to 1.0 90.9% (62.3%, 98.4%) < 1.0 to 0.5 90.0% (59.6%, 98.2%) < 0.5 to 0.2 93.3% (70.2%, 98.8%) Biochemical recurrence (Illuccix China study, n = 140)2 Patient level PPV 94.8% (95% CI: 85.9%, 98.2%) 1. Supported by guidelines3 2. Same day imaging 3. Reliability and dosing flexibility
Page 25
68Ga has a lower propensity for indeterminate bone lesions (IBLs)1,2 1. Kuchar M, et al. Molecules. 2015;20(9):16186-16220. 2. Rauscher I, et al. J Nucl Med. 2020;61(1):51-57. Free 68Ga, in contrast to 18F, does not have an affinity to bone 25 With 18F, a number of benign bone lesions accumulate PSMA and result in false positives on PSMA-PET/CT. SNMMI Guidelines for Prostate Cancer Imaging There are numerous advantages of having a more streamlined image pattern that guides you more to where the lesions are and avoids the distractions to where the lesions don't belong. - Dr. Munir Ghesani Gallium-68 Free 68Ga is taken up and metabolized through the liver and does not have an affinity to bone. Fluroine-18 Free 18F has a naturally high affinity to bone.
Page 26
Case study: diagnostic accuracy of 68Ga PSMA-11 1. Fendler WP, et al. PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging, 2023. 2. Lowrance W, et al. Updates to advanced prostate cancer. F-18 PSMA PET Scan PSA 3.4 • Patient on active surveillance • No active treatment IBL detected 68Ga PSMA-11 PET Scan 6 months later Resolution without interval treatment confirms lesion benignity Interpreting bone lesions with 18F-based PSMA radiotracers can be more challenging compared to 68Ga due to detection of benign bone lesions1,2 26 Patient case study from IIT: Intra-Individual Comparison of 68Ga- and 18F-Labeled PSMA PET for Skeletal Lesion Characterization in Prostate Cancer: A Pilot Feasibility, Study Interim Analysis led by Dr Ghesani. CT PET PET/CT Fused No rib lesion Patient representative scans – individual results may vary. Images are non-quantitative. -SNMMI Guidelines
Page 27
68-year-old male; Gleason 9 (4+5) prostate cancer; PSA is 112; Referred for 177Lu-PSMA Therapy (Pluvicto) 27 MIP1 Images 18F-PSMA PET Scan 68Ga PSMA-11 PET Scan Multiple lesions accurately identified on 68Ga PSMA-11 PET Scan, but not on 18F-PSMA PET Scan 1. Maximum Intensity Projection. Case Study Patient representative case study for educational purposes only. Individual responses may differ. Does not constitute medical advice or solicitation. Consult product labelling.
Page 28
50–100 mins Labelled acquisition window U.S. prescribing information for gallium 68Ga PSMA-11.1 68 mins Physical half-life of ⁶⁸Ga Approximately one quarter of administered activity remains at 150 min; decay is continuous, not a cut-off.1 >120 mins Permitted for indeterminate findings Joint EANM/SNMMI PSMA PET/CT guideline 2.0, including sites adjacent to the urinary tract.2 Beyond standard imaging, enhancing lesion detection through delayed 68Ga PSMA-11 PET imaging 1. Gozellix Prescribing Information April 2025. 2. Fendler et al., Eur J Nucl Med Mol Imaging 2023. 28
Page 29
EARLY scan standard acquisition DELAYED scan 150 mins extended list-mode, fractionally reconstructed Design Prospective pilot Enrolled 3 patients, prostate cancer Liver analysis 3 cases, fractional reconstructions Lesion analysis 13 paired lesions, 3 cases Study design evaluating delayed acquisition with 68Ga PSMA-11 ~60 mins 29
Page 30
Early · 60 mins Delayed · 150 mins Higher lesion-to-background contrast observed with delayed imaging Case study 1 using 68Ga PSMA-11 30 Patient representative case study for educational purposes only. Individual responses may differ. Does not constitute medical advice or solicitation. Consult product labelling..
Page 31
Early · 60 mins Delayed · 150 mins CT correlate · bilateral paratracheal nodes Higher lesion-to-background contrast observed with delayed imaging Case 2 using 68Ga PSMA-11 Paratracheal lymph nodes 31 Patient representative case study for educational purposes only. Individual responses may differ. Does not constitute medical advice or solicitation. Consult product labelling..
Page 32
10/ 13 lesions with higher delayed SUVpeak +8% median paired change · range −10.7% to +25.3% 1 h vs 50% delayed reconstruction · mean SUVpeak 5.60 vs 6.24 Delayed imaging with 68Ga PSMA-11 preserves lesion uptake, with a modest increase in SUV peak 32 Source: Study results provided by Dr. Munir Ghesani.
Page 33
PREVAILING ASSUMPTION “Delayed imaging is clearer because background tracer washes out.” PRIMARY HYPOTHESIS Early imaging yields superior overall lesion clarity and a more uniform hepatic background, because count density, not clearance, dominates perceived quality. Can delayed imaging with 64-Cu-DOTATATE improve lesion clarity adjacent to physiological uptake? Note: Study protocol developed and conducted by Dr. Ghesani. 33
Page 34
Design Retrospective, paired Cohort 20 patients, SSTR-positive NET Readers 3 board-certified NM physicians Display Matched anatomy, window, liver-normalized EARLY ~1 h post-injection DELAYED ~24 h post-injection Study design evaluating delayed acquisition with 64-Cu-dotatate A paired, within-patient design with blinded two-alternative forced choice 34 Note: Study protocol developed and conducted by Dr. Ghesani.
Page 35
MIP · 1 h MIP · 24 h Axial · 1 h Axial · 24 h 24-hour delayed imaging shows reduced image uniformity Case 1 using 64-Cu-dotatate 35 Patient representative case study for educational purposes only. Individual responses may differ. Does not constitute medical advice or solicitation. Consult product labelling. Note: Study protocol developed and conducted by Dr. Ghesani.
Page 36
MIP · 1 h MIP · 24 h Axial PET · 1 h Axial PET · 24 h CT correlate A hepatic lesion conspicuous at 1h was not visible at 24h Case 2 using 64-Cu-dotatate 36 Note: Study protocol developed and conducted by Dr. Ghesani. Patient representative case study for educational purposes only. Individual responses may differ. Does not constitute medical advice or solicitation. Consult product labelling.
Page 37
Axial PET · 1 h · no focal retroperitoneal uptake Axial PET · 24 h · left para-aortic focus CT correlate · retroperitoneal node, distinct from ureter A retroperitoneal lymph node absent at 1 hour became conspicuous at 24 hours Note: Study protocol developed and conducted by Dr. Ghesani. Case 3 using 64-Cu-dotatate 37 Patient representative case study for educational purposes only. Individual responses may differ. Does not constitute medical advice or solicitation. Consult product labelling.
Page 38
Combined review of both time points identified lesions that neither examination showed alone EARLY ALONE 104 lesions DELAYED ALONE 82 lesions COMBINED REVIEW 115 lesions · +11 over early alone Some lesions seen at 1 hour were no longer appreciable at 24 hours; some became apparent only after clearance of adjacent physiological activity. ⁶⁴Cu-dotatate results Variable lesion detection and heterogeneity between 1h and 24h with Cu imaging 38 Note: Study protocol developed and conducted by Dr. Ghesani.
Page 39
Initial biopsy protocol has remained unchanged since the addition of MRI Current state: PSMA-PET transformed staging and BCR detection PSMA-PET scans (in thousands) Initial staging 151 BCR 460 143 RLT selection 58 Monitoring for mAPMR progression Monitoring response to RLT 71 52 Response to treatment nmAPMR Disease progression Current indications Future indications Total addressable market Current TAM: ~670,000 scans/year TAM = Total addressable market, BCR = Biochemical recurrence, nmAPMR = non-metastatic androgen pathway modulation resistant, RPT = Radiopharmaceutical therapies. ClinicalTrials.gov: NCT07052214. Annual PSMA-PET scan volume in the U.S. based on internal estimates. 1M biopsies 39
Page 40
40 Potential to double the size of the existing PSMA market Future state: revolutionizes biopsy decision-making BiPASS = Biopsy of the Prostate Avoidance Stratification Study, TAM = Total addressable market, RPT = Radiopharmaceutical therapies, Annual PSMA-PET scan volume in the U.S. based on internal estimates. 1. Estimate one million biopsies performed in the U.S. each year. Source: Schmeusser et al. Therapeutic Advances in Urology, 2022. 2. ClinicalTrials.gov: NCT07052214. Current indications Future indications Total addressable market BCR Monitoring for mAPMR progression (pre-biopsy) Move imaging utilization to the pre-biopsy stage Initial staging reduced 1M+1 821,000 scans/ year Monitoring response to RLT Disease progression Biopsies reduced RLT selection Response to treatment to mAPMR
Page 41
Prostate cancer diagnosis Dr. Philip Dundee Urological surgeon
Page 42
Current diagnostic pathway for prostate cancer relies on invasive biopsies Template biopsy 1. Prostate Cancer Diagnosis | Johns Hopkins Medicine 2. Schmeusser B, Levin B, Lama D, Sidana A. Hundred years of transperineal prostate biopsy. Ther Adv Urol. 2022;14:17562872221100590. Published 2022 May 21. doi:10.1177/17562872221100590.https://www.researchgate.net/figure/Complications-of-transrectal-ultrasound-guided-prostate-biopsy_tbl1_10978264 3. Transperineal Biopsy Preparation | University Urology • Template biopsies require 15-20 samples obtained through an invasive procedure under anesthesia1 • Sampling limitations may miss disease or fail to characterize tumor burden. Biopsies are blind to the tumor location2 • Risks of infection, bleeding, urinary retention, post- procedural complications3 • Recovery times may vary from days to weeks4 • Multiple biopsies are often required to diagnose, monitor progression or confirm treatment response2 42
Page 43
A significant unmet need remains in the diagnostic pathway 43 Base (top) Apex (bottom) Men with elevated PSA values will often be recommended for MRI1, followed by biopsy • MRI is not specific and often inconclusive, leading to biopsy Areas of biopsy6 1. Magnetic resonance imaging. 2. Vickers et al. J Clin Oncol. 2010. 3. Ahmed et al. Lancet. 2017. 4. https://www.researchgate.net/figure/Complications-of-transrectal-ultrasound-guided-prostate-biopsy_tbl1_10978264 5. Filho et al., 2025. 6. Picture credit: Georgia Radiation Therapy. 7. Schmeusser B, Levin B, Lama D, Sidana A. Hundred years of transperineal prostate biopsy. Ther Adv Urol. 2022;14:17562872221100590. Published 2022 May 21. doi:10.1177/17562872221100590. Biopsy false-negative rates can be as high as 50%7 800,000 biopsies performed in the U.S. each year, up to 75% are negative2 • Biopsy is blind to the location of cancer in the prostate • Only ~half of the needles provide useful samples (false negatives)3 Up to 25% of patients refuse a recommended biopsy5 • Reasons for refusal include fear or pain of complications • Skepticism about the necessity of the procedure Biopsies carry real risks4 • Hematuria, rectal bleeding, hematospermia • Inconsistent practice around anticoagulants adds complexity
Page 44
Key insights from PRIMARY and PRIMARY2 Investigator Initiated Studies (IITs) PRIMARY (n = 291)1 Ga-PSMA-PET +mpMRI mpMRI Sensitivity 97% 83% Specificity 40% 53% Negative predictive value 91% 72% PRIMARY SCORE2 (analysis) Sensitivity 94% 89% Specificity 68% 74% P-Score3 (analysis) Sensitivity 94% 89% Specificity 66% 74% PRIMARY24 (n = 660) Ga-PSMA-PET +mpMRI Biopsy reduction 49% csProstate cancer detected 12% vs 16% PRIMARY study established proof of concept that Ga- PSMA-11 PET + mpMRI improves the detection of prostate cancer. PRIMARY2 study demonstrated that Ga-PSMA- 11 PET + mpMRI can safely reduce biopsies while maintaining a clinically significant detection of prostate cancer. 1. Emmett L, Buteau J, Papa N, et al. Eur Urol. 2021. 2. Emmett L, Papa N, Buteau J, et al. J Nucl Med. 2022. 3. Emmett L, Papa N, Hope TA, et al. J. Urol. 2024. 4. Buteau JP, Moon D, Fahey MT, et al. Lancet Oncol. 2026. 44
Page 45
Phase 3 study for detection of prostate cancer 45 Eligibility: Clinical suspicion of prostate cancer and indicated for template biopsy Status: Completed patient enrollment Global, multi center, open label, single arm study Clinicaltrials.gov: NCT07052214 68Ga-PSMA-11 + mpMRI PI-RADS 1-4 Template biopsy (targeted biopsy) Primary Objective: Detection of clinically significant prostate cancer using mpMRI + 68Ga-PSMA-11 PET1 Co-primary endpoints: Sensitivity and specificity n = 350 6- month follow-up (confirm negative findings) ® mpMRI = multiparametric Magnetic Resonance Imaging. 1. Histopathological confirmation will be used to detect prostate cancer. Biopsy of the Prostate Avoidance Stratification Study (BiPASS) Registrational study
Page 46
46 Image-guided biopsy Staging and surgical planning Precision biopsy 'One and Done' No biopsy 'None and Done' 68Ga PSMA-11 at diagnosis aims to: • Improve predictive accuracy • Reduce 12-40 anatomical biopsies to 1-2 biopsies • For some, eliminate the need for biopsy altogether • Decrease risk and anxiety Clinical goals: • Clearer treatment stratification • Personalized patient management • Expedited therapy Symptoms or elevated PSA PSMA-PET + mpMRI1 A more precise diagnostic pathway with 68Ga PSMA-11, enabling targeted use of biopsy 1. Multiparametric Magnetic Resonance Imaging. 2. Prostate Imaging Reporting and Data System, a scoring system used by radiologists to assess the likelihood of prostate cancer based on multiparametric mpMRI findings. PI-RADS2 1-4 PET Positive Potential high risk (PI-RADS2 5) PIRADS 1-2 PET Negative Risk stratification
Page 47
The future of prostate cancer detection 1. Celli M, Gunelli R, Ferroni F, Costantini M, Barone D, Fantini L, Fragalà E, Marini I, Di orio V, Foca F, Monti M, Matteucci F and Caroli P (2026) Toward a PSMA PET–mpMRI pathway for biopsy decision-making in men with suspected prostate cancer: interim results from the prospective BIOPSTAGE trial. Front. Oncol. 15:1720861. doi: 10.3389/fonc.2025.1720861. Current state 3 MRI acquisitions Future state 1 PSMA PET scan • 72 year old male was negative for suspicious findings (PI-RADS <3) • PSMA PET detected a focal uptake in the right anterior apex of the prostate1 Patient representative scans – individual results may vary. Images are non-quantitative. 47
Page 48
Brain cancer overview (select programs) Prof. Andrew Scott Head of Tumour Targeting Laboratory Olivia Newton- John Cancer Research Institute
Page 49
49 MAA = Marketing authorization application. EANM = European Association of Nuclear Medicine. EANO = European Association of Neuro-Oncology. RANO = Response Assessment in Neuro-Oncology. SNMMI = Society of Nuclear Medicine and Molecular Imaging. 1. Launch and brand names subject to final regulatory approval. 2. ASX release July 20, 2026. 3. Telix ASX disclosure September 14, 2026. 4. Telix ASX disclosure October 6, 2020. • Pixlumi ®1 MAA accepted in Europe • Included in National Comprehensive Cancer Network (NCCN®) guidelines • Inclusion in International guidelines: EANM/EANO/RANO/SNMMI • Expanding into new indication: brain metastases2 • Addresses high unmet need – helps to differentiate tumor progression vs. treatment effects3 • Granted orphan drug designation4 First-in-class imaging agent approved for glioma1 First FDA approved imaging agent for gliomas (U.S.)
Page 50
Clinician impact Insights based Shoreline Research, Awareness trial and utilization report, January 2026. Key insights ~70% of physicians surveyed indicated they are ready to prescribe Pixclara upon FDA approval ~80% of referrers rely on NCCN guidelines when ordering imaging for glioma >90% availability of PET scanners in-house Majority of referrers rank high differential uptake in glioma and high image quality as the most important features of a PET radio tracer 50
Page 51
• Large amino acid transporters, LAT1 and LAT2 are highly expressed in gliomas1,2 compared to normal tissue • LAT1 is expressed on both luminal and abluminal membranes, playing a key role in BBB permeation2,3 • Pixclara targets LAT1 and LAT2 while TLX101-Tx and TLX102-Tx therapeutic candidates target LAT1 A novel mechanism of action overcoming the blood brain barrier Targeted radiation that provides imaging and therapeutic potential 1. Singh N and Ecker GF. Int J Mol Sci. 2018;19(5):1278. 2. Haining Z, et al. BMC Clin Pathol. 2012;12:4. 3. Ahmed HS. Mol Neurobiol. 2025;62(3):3813-3832. Pixclara TLX101-Tx (131I) TLX102-Tx (211At) Pixclara TLX101-Tx (131I) TLX102-Tx (211At) Blood (luminal) Brain (abluminal) 4F2hc LAT1 C N S-S 51 A potential first-in-class theranostic pairing in neuro-oncology
Page 52
Our amino acid PET tracer, TLX101-Px represents an innovative advancement in imaging Existing imaging modalities have meaningful limitations Note: CE-MRI = contrast enhanced MRI, TBR = Tumor to background ratio 1. Law I, Albert NL, Arbizu J, et al. Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0. Eur J Nucl Med Mol Imaging. 2019;46(3):540-557. 2. Rosen J, Ceccon G, Bauer EK, et al. Cost effectiveness of 18F-FET PET for early treatment response assessment in glioma patients after adjuvant temozolomide chemotherapy. J Nucl Med. 2022;63(11):1677-1682. 3. NCCN Guidelines: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1425. Pixclara brand name is subject to final regulatory approval. A side-by-side comparison of sequential T1-weighted post contrast MRI and 18F-FET of the same patient Post-contrast MRI scan showing an enhancing region that was inconclusive 18F-FET demonstrated focal uptake laterally near the margins of the resection cavity with a TBRmax of 3.2, meeting the threshold for recurrent disease Limitations of CE MRI MRI, the current SoC for imaging of gliomas, yields inconclusive results1,2 • Fails to reflect the entire extent of glioma, leading to undertreatment • Mistake treatment related changes as tumor recurrence, leading to over treatment Combining amino acid PET tracers with anatomical MRI improves diagnostic accuracy in primary and secondary brain tumors3 and supports clinical decision making MRI 18F-FET PET Patient representative scans – individual results may vary. 52
Page 53
Comparison of FET PET with standard MRI for the detection of tumor tissue Imaging findings were evaluated histologically 53 Pauleit et al. Brain. 2005. Patient representative scans – individual results may vary. Combining TLX101-Px with MRI has demonstrated sensitivity of 93% and specificity of 94% for detection of gliomas Only the biopsy of the FET hot spot yielded tumor tissue CNS WHO grade 3 astrocytoma Reactive astrogliosis MRI alone Sens, 96%; Spec., 53% MRI & FET PET Sens, 93%; Spec., 94% TPF 1 0.5 0 0.50 1 FPF
Page 54
A 35-year-old patient with initial diagnosis of a diffuse astrocytoma (WHO grade II). Follow-up MRI 86 months after initial diagnosis showed a slight progression of the hyperintensity in the T2-weighted MRI, but no clear contrast enhancement in the right temporal. In contrast, 18F-FET shows highly increased metabolic activity (TBRmax, 3.9) in the right temporal, and the time–activity curve shows an early 18F-FETuptake (20 min) followed. After a stereotactic-guided biopsy of the metabolically active tumor, histological examination was consistent with a malignant progression to an anaplastic oligoastrocytoma (WHO grade III). Patient representative scans – individual results may vary. 54 Galldiks, et al. The use of dynamic O-(2-18F-fluoroethyl)-L-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma. Neuro-oncology vol. 2015. TLX101-Px in combination with MRI differentiates between treatment related changes and disease progression
Page 55
Note: TMZ = temozolomide, PTEN = phosphates and tensin homolog, EGFR = epidermal growth factor receptor, TCGA = the cancer genome atlas, IDH1/2 = isocitrate dehydrogenase 1 and 2. Standard of care has remained unchanged for the past two decades despite rapid innovation in oncology 55 FDA Approvals 1st CT Levin Criteria: CT EGFR Lomustine Radiotherapy Carmustine Gliadel Wafers 1970 1980 1990 2000 2010 2020 2030 TMZ for recurrent anaplastic astrocytoma TMZ for newly diagnosed GBM Bevacizumab for recurrent GBM Tumor treating fields 1st MRI McDonal criteria: MR steroids RANO criteria PTEN TCGA Subtype WHO Classification based on IDH1/2 Imaging, criteria and biomarkers 55 Vorasidenib for LGG IDH mutant Pixclara approval GBM presents a significant and persistent unmet need for patients
Page 56
~25k new brain and CNS tumor cases/yr with ~18k deaths/yr (U.S.)1 GBM is the most common and most aggressive type of brain cancer, accounting for ~50% of all malignant CNS tumors or ~15k+ patients/year2 Disease overview: Glioblastoma (GBM) Burden of GBM is increasing, however survival rates have not improved in 20+ years1 CNS: central nervous system. 1. American Cancer Society (Cancer Facts & Figures 2025). 2. Grochans S, et al. Cancers (Basel). 2022;14(10):2412. 3. Nahm et al. J Clin Oncol 41, e14057(2023). Annual incidence (US)1 Average survival (U.S.)1 4 0 2 1975 1985 1995 2005 2015 2022 Year of Diagnosis Rate per 100,000 Relative Survival (%) 60 0 20 40 200 2004 2008 2012 2016 2022 Year of Diagnosis 56 Patients with GBM have a median overall survival of 12-15 months1 from diagnosis and 3-9 months from recurrence3
Page 57
Prior TLX101-Tx studies have demonstrated favorable safety profile and encouraging efficacy in malignant gliomas 1. Investigator-initiated trial referring to clinical study report (CSR), 2. Across various trials (IPAX-1, IPAX-Linz, IPAX-2, IPAX BrIGHT) and compassionate use program. 3. Telix media release May 19, 2026. Our strategy is to establish clinical proof in later-line disease before expanding into earlier treatment Demonstrated safety and tolerability profile in combination trials with EBRT and TMZ • IPAX-1 (Phase 1), IPAX Linz1 (Phase 2), IPAX-2 (Phase 1), compassionate use program • Treated ~60 patients to date, including pediatric patients2 • Well tolerated, no DLTs observed in IPAX-23 Demonstrated early efficacy results • Median OS of 23mo. (IPAX-1) and 32.2mo. (IPAX-Linz1) from initial diagnosis • Median OS of 13mo. (from initiation of treatment, IPAX-1) and 11.9mo. (from progression prior to start of treatment, IPAX-Linz1) Ongoing trials • Phase 3 trial, IPAX BrIGHT, in combination with lomustine, first recurrence – dosing patients • Phase 1 trial, IPAX-2, in newly diagnosed patients – completed enrollment, awaiting readout 57
Page 58
1. Europe includes Austria, Belgium, Denmark, France, Germany, Netherlands, Spain where we have regulatory approvals or filings. 2. IND currently under review. , A global Phase 3 study for TLX101-Tx 58 Data review Conventional MRI and 18F FET PET used for imaging response Eligible Patients Part 2: Randomized treatment expansionPart 1: Dose optimization • Ages ≥18 years • Confirmed recurrent glioblastoma TLX101-Tx + Lomustine Lomustine Clinicaltrials.gov: NCT07100730 Eligibility: recurrent GBM (WHO 2021), 18 years+ Status: Study open to enrollment in Austria, Australia, Belgium and Netherlands. Regulatory authorizations to proceed in Denmark, France, Germany, Spain and Singapore. IND filed to expand the study to the U.S. Global, multi center, prospective, open label study Primary endpoints (Part 1) • Max tolerated dose, MTD and recommended dose for Part 2 Primary endpoint (Part 2) • Overall survival (OS) If combination dose not tolerated, lower either TLX101-Tx dose and/or Lomustine. Mono therapy is an option n = up to 50 Europe Singapore U.S. 1 2 TLX101-Tx (4 GBq) + Lomustine (90 mg/m2) x 3 cycles n = 3 TLX101-Tx (4 GBq) + Lomustine (90 mg/m2) x 3 cycles n = 12 1:1 TM
Page 59
Demonstrated favorable safety and tolerability in compassionate use program 1 - Grade 3 adverse events, cerebral edema (1), common for this condition, judged not likely due to TLX101-Tx - No Grade 4 adverse events TLX101-Tx, has demonstrated a favorable safety profile, with stable disease observed 1. Named patient program, UMC Utrecht. Sturre TAJ et al IODO-RISE, presented at EANM 2026. RANO Response Criteria MRI RANO PET RANO* Stable disease (SD) 3 of 12 3 of 7 Partial Response (PR) 0 of 12 1 of 7 Progressive disease (PD) 9 of 12 3 of 7 59 Over 26 patients have been treated with TLX101-Tx in our compassionate use program in Austria, Australia, Germany, Netherlands, New Zealand and USA with no Grade 4 adverse events reported *PET follow-up (18F-Floretyrosine) only available in 7 of 12 patients TLX101-Tx tumor uptake Patient representative scans - individual results may vary. Results of a cohort of 12 GBM, Oligodendroglioma and Astrocytoma brain tumors patients treated at a single center:
Page 60
IPAX-2, Phase 1 study for TLX101-Tx (newly diagnosed GBM) Met Primary endpoint: Max Tolerated Dose (MTD) of 5GBq x 2cycles + SoC achieved Conventional MRI and [18F]FET PET used for imaging Austria Netherlandsn = 12 SoC = Maximal safe resection followed by concomitant EBRT + TMZ and adjuvant TMZ SoC = standard of care. EBRT = external beam radiation therapy, TMZ = temozolomide. 1. Post surgical resection and prior to systemic therapy or radiation therapy for GBM. Clinicaltrials.gov: NCT05450744 Global, multi center, open label, single arm study Primary endpoints • Safety and tolerability • Max tolerated dose and recommended dose Dose escalation TLX101-Tx (4 GBq) x2 cycles + SoC TLX101-Tx (3 GBq) x 2 cycles + SoC TLX101-Tx (5 GBq) x2 cycles + SoC Eligibility: newly diagnosed glioblastoma patients1 Status: Study enrollment completed Results: no dose limiting toxicities observed at maximum dose of (5 GBq) x 2 cycles within DLT window (63 days) Next steps: data supports advancement into Phase 2 study 60
Page 61
Renal cancer (select programs) Dr. David N. Cade Group Chief Medical Officer
Page 62
Disease overview: Kidney cancer 14th most commonly diagnosed cancer worldwide1 Age-standardized incidence & mortality highest in North America & Europe1 Twice as common in men vs women1 90% of kidney cancer is RCC, of which ~85% is ccRCC2,3 Age-standardized rate per 100,000 (2022)4 ccRCC, clear cell renal cell carcinoma; RCC, renal cell carcinoma. 1. Bray F, et al. CA Cancer J Clin. 2024;74(3):229-263. 2. Qi X, et al. Front Oncol. 2021;11:727778. 3. Alchahin AM, et al. Nat Commun. 2022;13(1):5747. 4. Globocan 2022 (version 1.1) - 08.02.2024. https://gco.iarc.who.int. 62
Page 63
Novel target in ccRCC - CAIX 1. CAIX, carbonic anhydrase IX; ccRCC, clear cell renal cell carcinoma. 2. 1. Aldera AP, et al. J Clin Pathol. 2021;74(6):350-354. 2. Becker HM. Br J Cancer. 2020;122(2):157-167. 3 3. Wykoff CC, et al. Cancer Res 2000;60(24):7075–7083. 4. Maxwell PH, et al. Nature 1999;399(6733):271–275. 5. Courcier J, et al. Int J Mol Sci 2020;21(19):7146. 6. Bui MHT, et al. Clin Cancer Res 2003;9(2):802– 811. 7. Stillebroer AB, et al. Eur Urol 2010;58(1):75–83. Adapted from Becker HG.2 63 Transmembrane glycoprotein involved in oxygen-sensing pathways and regulator for pH1,2 Induced by hypoxia or by mutation of the Von Hippel-Lindau tumor suppressor gene1-4 Expressed in >95% of ccRCC5-7 Negligible expression in normal kidney tissue7
Page 64
Monoclonal antibody-based theranostics CAIX, carbonic anhydrase IX; PET, positron emission tomography. 1. Oosterwijk-Wakka et al. Int J Mol Sci. 2013;14(6):11402-23; 2. Kulterer et al. J Nucl Med. 2021;62(3):360-5. 3. Merkx et al. Eur J Nucl Med Mol Imaging. 2021;48(10)3277-85 4. Chamie et al, 2-15. Girentuximab • IgG1 kappa light chain chimeric monoclonal antibody • Girentuximab - highly specific binding to CAIX and internalization • Safety data from Phase 1-3 clinical studies with girentuximab in RCC, including nearly 500 patients and healthy volunteers1- 4 • Hepatic clearance Payload: 89Zr (imaging) • Positron emitter • Half-life 3.3 days • Suitable for antibody-based PET imaging Payload: 177Lu (therapy) • Medium-energy β-emitter • Half-life 6.7 days • Suitable for antibody-based therapy 64 TLX250-Tx for treatment of ccRCC and TLX250-Px for imaging
Page 65
TLX250-Px: ZIRCON imaging data validates target in ccRCC CAIX, carbonic anhydrase IX; ccRCC, clear cell renal cell carcinoma; mAb, monoclonal antibody; PET, positron emission tomography; rADC, radio antibody-drug conjugate; T1/2, half-life. Shuch B, et al. Lancet Oncol. 2024;25(10):1277-1287. ZIRCON ClinicalTrials.gov ID: NCT03849118. 65 ZIRCON study results summary Sensitivity & specificity of small lesions ≤4 cm (n=145) • Sensitivity: 85% • Specificity: 90% ≤2 cm (n=20) • Sensitivity: 97% • Specificity: 97% Reader agreement The Fleiss’ κ statistic for inter- reader variability: 91% Cohen's κ statistic for intrareader variability: 100% for each reader Safety & tolerability Favorable profile indicated Primary endpoints: (n=284) Sensitivity: 86% | Specificity: 87% Phase 3 imaging trial and real-world evidence have important insights for therapy program
Page 66
TLX250-Tx: LUTEON (Ph3) and LUTEON-ATLAS (Ph2a) trial design HREC = Human Research Ethics Committee, ccRCC = clear cell renal cell carcinoma, DR1 = Dosing regimen 1, DR2 = Dosing regimen 2, PET = positron emission tomography, R= randomization, RP3D = recommended Phase 3 dose, SoC = Standard of care. AUS sites enrolling patients1 U.S. sites enrolling patients / EU under review Population: • Advanced or metastatic ccRCC • Disease progression on/after 2 to 3 prior systemic lines of therapy • CAIX-positive by 89Zr-TLX250 PET Part 1: Dose Optimization (Phase 2a) Treatment period (months) 1:1 1887 MBq 1887 MBq 1887 MBq 1258 MBq 1258 MBq 1258 MBq 1258 MBq 1258 MBq 1258 MBq 1 2 3 4 5 6 RP3D N=TBD N=TBD Part 2 (Phase 3) Investigators choice (SOC) Dose administration 1-month intervals 2-month intervals 1:1 177Lu-TLX250 (RP3D) US/EU: LUTEON-ATLAS (Ph2a) AUS: LUTEON (Ph3) 1. ClinicalTrials.gov ID NCT07197580, Telix media release July 21, 2026. 2. Australia: recruiting, U.S.: recruiting, Europe: application under review. 66 1,887 MBq 1,258 MBq Safety Lead-in* N=3 N=3 RP2a *3 pts in Safety Lead-in included in total 20 pts in Part 1 (Dose Optimization); No Safety Lead-in in AUS DR2 = 20 DR1 = 20 Global study locations2 ClinicalTrials.gov ID NCT07197580
Page 67
Dr. David N. Cade Group Chief Medical Officer, CMO TLX591-Tx
Page 68
Disease progression shifts clinical priorities Distinct prostate cancer disease states bear implications for patient management SOURCES: 1. Kyriakopoulos et al. J Clin Oncol. 2018, Fizazi et al. Lancet Oncol. 2019 2. Armstrong et al. Eur Urol. 2020; Ryan et al. Lancet Oncol. 2015 Androgen pathway modulator sensitive Androgen pathway modulator resistant Prognosis and patient profile Disease biology • Survival commonly extends beyond 4-5 years1, generally fitter patients • Approximately 2-3 years from initiation of 1L therapy2, greater clinical complexity • Variable tumor burden, more localized • Responsive to androgen suppression • Increasing tumor burden • Progressively resistant phenotypes Clinical implication • Intensify treatment to delay progression to mAPMR • Preserve long-term quality of life • Optimize sequencing across limited options • Maximize efficacy at each treatment line mAPMR: metastatic androgen pathway modulator-resistant. NOTE: Illustrative ranges; outcomes vary by disease volume, prior treatment, patient characteristics and therapy. 68
Page 69
Addressing patient needs across the care continuum TLX597-Tx and TLX591-Tx profiles are adapted to each disease state TLX591-Tx: First-in-class rADC2 TLX597-Tx: Next gen small molecule1 1. Kahn at al. Dose Optimisation and PSMA Receptor intensification with 177Lu-PSMA-597 in metastatic castration-resistant prostate cancer, the Randomised Phase II OPTIMAL-PSMA trial, presented at IPCS / APCCC 2026; Omar et al, [177Lu]Lu-DOTA-HYNIC-panPSMA radioligand therapy for patients with metastatic castration-resistant prostate cancer, presented at EANM 2025 2. Sartor et al. Presented at: American Society of Clinical Oncology Annual Meeting 2024; TPS5115; Sun et al. Curr Oncol Rep. 2021; Lenzo et al. Cancers (Basel). 2026; Tagawa ST, et al. Cancer. 2019. Excretion organ Kidney and salivary gland impact Efficacy signal • Liver excretion (radio-tolerant organ) with minimal dose to kidneys • Renal excretion BUT with 1/3rd radiation dose to kidney vs PSMA-617 • Limited kidney dose and negligeable salivary gland uptake • Limited kidney dose, radiation to salivary gland 1/5th vs PSMA-617 • rPFS of 8.8 months in ProstACT SELECT trial • High lesion dosimetry, positive signals from OPTIMAL-PSMA and PTherpan-Lu Dosing • 2 doses of 76 mCi enables combination with mAPMR SOC (ARPI and chemo) • 3-7 doses of 230mCi adaptively administered to limit overtreatment mAPMN/S mAPMR 69
Page 70
TLX591-Tx is a novel therapy candidate for prostate cancer 1. Patient friendly 2-dose / 2-week regimen: Supports compliance to treatment and ease of integration with standard of care (SOC) 2. Safety and tolerability profile: Low radiation to salivary glands and kidneys, transient and manageable hematologic profile 3. Internalization and prolonged retention: Delivering a payload to the tumor, potentially maximizing cell killing effect 4. Supply, access, and radiation protection: Potential real-world advantages from lower administered activity (76 mCi per dose) Radio antibody-drug conjugate (rADC) approach addresses key unmet needs1-4 Mechanism of Action 70 1. Sartor O, et al. Presented at: American Society of Clinical Oncology Annual Meeting 2024; TPS5115. 2. Sun M, et al. Curr Oncol Rep. 2021. 3. Lenzo et al. Cancers (Basel) 2026. 4. Tagawa ST, et al. Cancer. 2019.
Page 71
Phase 3 study for TLX591-Tx Data review Eligible Patients Part 2: Randomized treatment expansionPart 1: Safety and dosimetry: completed • Ages ≥18 years • Confirmed recurrent glioblastoma Clinicaltrials.gov: NCT06520345 Eligibility: mAPMR2 patients progressing on first ARPI Status: Enrolling patients in Part 2 globally8 (Japan approved for Part 1) Global, multi center, open label study Primary endpoints (Part 1) • Safety and dosimetry Primary endpoint (Part 2) • rPFS6 by BICR7 TLX591-Tx (76mCi) x 2 cycles + abiraterone n = 10 TLX591-Tx + abiraterone/ enzalutamide/ docetaxel abiraterone enzalutamide docetaxel 2:1TLX591-Tx (76mCi) x 2 cycles + enzalutamide n = 10 TLX591-Tx (76mCi) x 2 cycles + docetaxel n = 10 South Korea Singapore Part 1 completed, with FDA alignment to advance to Part 2 in U.S.1 n = 30 n = ~490 ® 71 1. Following FDA review and alignment of the Part 1 safety data, Telix is finalizing its IND amendment to support progression to Part 2 of the ProstACT Global Phase 3 study in the U.S. 2. Metastatic androgen pathway modulation resistant prostate cancer. 3. Safety & tolerability reported as adverse events. 4. Independent Data Monitoring Committee review, October 2025. 5. Japanese regulator has granted approval for a Japan-specific Part 1 in nine patients, prior to commencing Part 2. 6. Radiographic progression-free survival. 7. Blinded independent central review. 8. Australia, New Zealand, Canada, Singapore, South Korea, Türkiye and UK.
Page 72
Patient case: TLX591-Tx (2 doses) + docetaxel (6 cycles) 1. Thoracic vertebrae, ribs. 2. ProstACT Global Part 1 data on file. Telix Pharmaceuticals. SPECT TLX591-Tx biodistribution: Single dose Distribution of TLX591-Tx over 15 days2 BASELINE PET 4 hours 1 day 4 days 7 days 15 days* TLX591-Tx seen in the vascular space and liver TLX591-Tx seen at metastatic sites (and liver) * 83-year-old patient with bony metastatic lesions1 Post treatment SPECT imaging after one injection of TLX591-Tx 72 Patient representative scans – individual results may vary. Images are non-quantitative. Stable disease at day 341 (data cutoff)
Page 73
Patient case: TLX591-Tx (2 doses) + abiraterone TLX591-Tx, 177Lu-rosopatamab 1. Subcarinal, right upper para-tracheal, abdominal, pelvic lymph nodes. SPECT TLX591-Tx biodistribution: Single dose distribution of TLX591-Tx over 15 days BASELINE PET 4 hours 1 day 4 days 7 days 15 days* TLX591-Tx seen in the vascular space and liver TLX591-Tx seen at metastatic sites (and liver) * 64-year-old patient with metastatic disease in lymph nodes1 73 Stable disease for 339 days Post treatment SPECT imaging after one injection of TLX591-Tx Patient representative scans – individual results may vary. Images are non-quantitative.
Page 74
Patient case: TLX591-Tx (2 doses) + enzalutamide TLX591-Tx, 177Lu-rosopatamab 1. Subcarinal, right upper para-tracheal, abdominal, pelvic lymph nodes. SPECT TLX591-Tx biodistribution: Single dose distribution of TLX591-Tx over 15 days BASELINE PET 4 hours 1 day 4 days 7 days 15 days* TLX591-Tx seen in the vascular space and liver TLX591-Tx seen at metastatic sites (and liver) * 62 year-old patient with prior ARPI (darolutamide) and docetaxel1 74 Stable disease and on study at 337 days (data cutoff) Patient representative scans – individual results may vary. Images are non-quantitative. Administration of first dose of TLX591-Tx
Page 75
TLX597-Tx Prof. Louise Emmett Director of Theranostics and Nuclear Medicine St Vincent’s Hospital Sydney
Page 76
TLX597-Tx: Next-Generation PSMA-targeting RLT Key differentiators 1. Small-molecule PSMA ligand 2. High tumor uptake and retention2 3. Low salivary gland uptake2 4. Low kidney uptake2 5. Potential for dose intensification3 TLX597-Tx, small molecule candidate with promising early safety and dosimetry data1 76 1. Steinhelfer et al. J Nucl Med. 2024. 2. Final dosimetry report for PSMA-597 (Ascinta Technologies). 3. Crumbaker at al. Dose Optimisation and PSMA Receptor intensification with 177Lu-PSMA-597 in metastatic castration resistant prostate cancer, the Randomized Phase II OPTIMAL-PSMA trial, presented at ASCO GU 2026. Targeted mechanism supports enhanced tumor selectivity Localized radiation induces tumor cell death Low uptake in salivary glands and kidneys supports improved tolerability and wider therapeutic window
Page 77
TLX597-Tx early data suggests favorable dosimetry profile Selective tumor targeting with lower healthy tissue exposure TLX597-Tx SPECT scan, 5 hrs and 120 hrs Kidneys 0.28 0.58 0.71 Lacrimals 0.35 1.58 2.83 Submandibular 0.25 0.74 0.64 Lesions (bone) 9.74 3.57 4.1 Lesions (soft tissue) 9.57 4.19 2.94 Patient representative scans – individual results may vary. TLX597-Tx (n = 12)1 PSMA-6172 (n = 297) PSMA-I&T2 (n = 153) 1. Khan et al. J Nucl Med. 2026. Final dosimetry report for PSMA-597 (Ascinta Technologies). 2. Ells et al Dosimetry of [177Lu]Lu-PSMA–Targeted Radiopharmaceutical Therapies in Patients with Prostate Cancer: A Comparative Systematic Review and Meta analysis. JNM 2024; 65:1264–1271. < < < > > 5 hrs 120 hrs Gy/GBq 77
Page 78
Leveraging dose intensification and higher activity to enhance tumor response PSMA up-regulation can be seen 3 days after the initial dose through higher TTV Dose 1 (Day 1) Dose 2 (Day 3) SUV mean 5.7 SUV max 25 TTV 2379 mL SUV mean 7.9 SUV max 74 TTV 3977 mL 1. Crumbaker at al. Dose Optimisation and PSMA Receptor intensification with 177Lu-PSMA-597 in metastatic castration-resistant prostate cancer, the Randomized Phase II OPTIMAL-PSMA trial, presented at ASCO GU 2026. Day 1 8.5GBq (230mCi) Day 3 8.5GBq Day 15 8.5GBq Week 10 8.5GBq Week 20 8.5GBq Week 30 8.5GBq First 3 doses administered in 15 days Dose intensification consists of 2 components Higher administered activity of 8.5GBq/dose vs 7.5GBq 1 2 Dose intensification and higher activity are enabled by a favorable safety profile and biodistribution The rationale is to exploit upregulated PSMA expression and incomplete tumor DNA repair Patient representative scans - individual results may vary. 78
Page 79
TLX597-Tx, Phase 2 OPTIMAL-PSMA study Exploring safety and efficacy of dose intensification vs standard treatment Investigator Initiated Trial (PI: Prof Louise Emmett, St Vincent’s Hospital, Sydney) Day 1 8.5GBq (230mCi) TLX597-Tx* Dose Intensified TLX597-Tx Standard of Care n = 80 2:1 Eligibility • Confirmed mAPMR • Progressed on prior ARPI • Baseline 68Ga- PSMA-11 ENZA-p criteria (SUV max >15 at single site and >10 at larger sites) Primary Endpoints • PSA90 RR Secondary Endpoints • PSA50 RR • PSA-PFS • rPFS • OS • ORR • QoL • Safety • Dosimetry n = 40 Day 3 8.5GBq Day 15 8.5GBq Week 10 8.5GBq Week 20 8.5GBq Week 30 8.5GBq Day 1 7.5GBq (200mCi) Week 6 7.5GBq Week 12 7.5GBq Week 18 7.5GBq Week 24 7.5GBq Week 30 7.5GBq Initial 3 doses in 15 days Last 3 doses every 10 weeks 6 doses every 6 weeks 30 weeks of treatment in both arms Part B 68Ga-PSMA-11 PSA at week 8 in both arms Majority of patients received prior taxane ANZCTR Registration Number: ACTRN12625000971437. 1. Pathmanandavel S, et al. J Nucl Med. 2022;63:1343-1351. 2. John N, Pathmanandavel S, et al. J Nucl Med. 2022;64:410-415. 3. Sheehan B, et al. Clin Cancer Res. 2022;28:3104-3115. 79 n= 120 PSA response as well understood surrogate biomarker for small molecules (not for mAbs)
Page 80
Patient case: TLX597-Tx treatment post-chemo (2 lines) and ARPI 71-year-old patient with diffuse bone metastases • Normal kidney function • Substantial shrinkage of lesions • 97% PSA response at week 10 Dose 1 (Day 1) Dose 2 (Day 3) Dose 3 (Day 15) Dose 4 (Week 10) NOTES: Hb: hemoglobin. PLT: Platelets. eGFR: estimated glomerular filtration rate (renal function). Source: Data on file, L. Emmett. Day 1 Day 3 Day 15 Week 6 Week 10 PSA 1,380 1,480 828 131 40 Hb 112 111 117 116 106 PLT 201 198 217 190 208 eGFR 90 90 90 90 89 80 Patient representative scans - individual results may vary.
Page 81
Patient case: TLX597-Tx in advanced setting Extensive skeletal / bone marrow involvement at baseline • Improvement in hemoglobin • Normal kidney function • 99% PSA response Dose 1 (Day 1) Dose 2 (Day 3) Dose 3 (Day 15) NOTES: Hb: hemoglobin, PLT: Platelets, eGFR: estimated glomerular filtration rate (renal function). Advanced setting refer to disease progression post ARPI, received chemotherapy/medically unfit to receive chemotherapy. Source: Data on file, L. Emmett. Day 1 Day 3 Day 15 Week 10 Week 20 PSA 487 522 358 27 1.9 Hb 81 77 113 67 106 PLT 130 123 109 130 244 eGFR 77 75 81 85 83 Dose 4 (Week 10) Dose 5 (Week 20) 81 Patient representative scans - individual results may vary.
Page 82
Eligibility • Minimally treated mAPMN/S • High risk metachronous / synchronous • ADT < 30 days • Baseline PSMA- PET using VISION Criteria Primary endpoint • PSA <0.2ng/mL at 6mo. Secondary endpoints • Safety • PSMA PET response • PSA 50% & 90% RR • ORR • QoL • Dosimetry Day 1 ARPI4 Dose 1 Day 8 8.5GBq Dose 2 Day 10 8.5GBq Dose 3 Week 6 8.5GBq 3 doses in 6 weeks Dose 4 Week 14 8.5GBq Dose 5 Week 22 8.5GBq Dose 6 Week 30 8.5GBq Screening Continuous ADT + ARPI 2 doses every 8-weeks Week 12 PSMA PET/CT Scan & PSA test1 Week 24 PSMA PET/CT Scan & PSA test2 1. After Dose 3, treatment pause is allowed in participants with >90% reduction in volume, no residual large lesions and no new lesions and PSA < 1ng/mL, or in participants with residual PSMA avid disease confined to the prostate only who then receive prostate radiotherapy). 2. After Dose 5, participants who have not had a [177Lu]Lu-PSMA-597 treatment-pause, have a PSA < 1ng/mL, and a >90% reduction in volume, no residual large lesions and no new lesions on the 24-week PSMA PET/CT, will be eligible for a treatment pause. 3. Following 7 doses, an additional 3 doses (7+3) of [177Lu]Lu-PSMA-597 can be given in responding participants at the discretion of the treating investigator. 4. abiraterone, apalutamide, darolutamide, enzalutamide. Dose 7 Week 38 8.5GBq 2 doses every 8-weeks Week 44 PSMA PET/CT Scan & PSA test3 Week 1 ADT Adaptive PSMA targeted radioligand therapy TLX597-Tx, Phase 2 OPTIMAL-e study in mAPMN/S (mHSPC) 82
Page 83
Case study: OPTIMAL-e 83 Source: Emmett, L. Next-generation PSMA therapeutics: The OPTIMAL trial experience, presented at EANM 2026, used with permission. Patient representative scans - individual results may vary.
Page 84
Dr. David N. Cade Group Chief Medical Officer, CMO Prostate cancer
Page 85
Multi-product therapy portfolio in prostate cancer Androgen pathway modulator-sensitive Androgen pathway modulator resistant PSA tumor burden mAPMN/S 3L+ mAPMR2L mAPMR1L mAPMR Global TLX591-Tx Phase 2a in PSMA+ mAPMN/S patients TLX597-Tx OPTIMAL-e TLX592-Tx TLX090-Tx Palliative Phase 3 in PSMA+ mAPMR patients previously treated with 1 ARPI Aligned to disease state, patient needs and clinical opportunity 85 mAPMN/S = metastatic androgen pathway modulation naïve/sensitive; mAPMR = metastatic androgen pathway modulation resistant.
Page 86
Financial overview Darren Smith Chief Financial Officer
Page 87
Financial strength creates strategic choice A scaled commercial base enables strategic investment for long term value creation 2026 REVENUE GUIDANCE US$950–970M1 PRECISION MEDICINE GROSS MARGIN 65%2 NET PROFIT AFTER TAX US$38M2 CASH BALANCE US$252M3 1 Commercial scale Commercial execution of Precision Medicine and Therapeutics businesses diversifies revenue and generates cash 2 Strategic optionality and disciplined investment Commercial success unlocks optionality – flexibility across late- stage pipeline, infrastructure and M&A 3 Vertical integration strengthens financial position Control of critical supply chain reduces risk and improves profitability Commercial scale | Profitability | Investment Long term value creation 87 1. First instance of guidance provided in ASX release February 20, 2026, reaffirmed in ASX release October 21, 2026. 2. H1 2026 results ASX release August 20, 2026. 3. As of June 30, 2026. ASX release August 20, 2026.
Page 88
Group revenue US$M 56% 88 TMS = Telix Manufacturing Solutions. 1. Refers to revenue guidance of $950M - $970M for FY2026 and $40M (Other Income), Telix ASX disclosure October 21, 2026. Year over year growth based on upper end of guidance. 2. TMS revenue from third parties. RLS is the largest component of TMS, contributing to third party revenue. Excludes revenues from Illuccix and Gozellix sold through RLS. 2022 2023 2024 2025 2026F 950 - 9701 804 517 Global revenue excluding TMS TMS revenue2 ~20% Consistent commercial execution driving sustained growth COMMERCIAL SCALE1 333 107 211% 55% 56%
Page 89
Disciplined capital allocation for sustainable growth 89 R&D investments Investment in the therapeutics and precision medicine pipeline Commercial investments Optimize sales performance, globally Strategic growth opportunities (M&A) Accelerate strategy, innovation, pipeline, scale and capabilities. Lifecycle management Supply resilience Supply chain resilience and production capacity Capital prioritized for measurable milestones and high-value inflections Capital allocation Strategic optionality2
Page 90
90 R&D investment focused on late-stage assets Telix R&D investment below peer average R&D spend as % of revenue(1) R&D as % of revenue(1) ✓ R&D investment tied to measurable milestones, clinical evidence and maximum value ✓ ✓ Commercial scale and pipeline progress achieved with R&D investment below therapeutics peers’ average R&D spend 35% Disciplined R&D investment supported by commercial scale 2. Benchmarking source: Visible Alpha estimates, Wall Street Research. As of October 2026. Average excluding Telix. 1. Refers to the midpoint of the revenue guidance of $950M - $970M for FY2026 and the midpoint of the R&D guidance of $240 - $260M, Telix ASX disclosure October 21, 2026. Focus capital on opportunities that can expand patient access and support long-term growth Disciplined investment2 Average: 35% (2)
Page 91
ITM Combines Strong Revenue Growth with a Clear Path to Positive EBITDA 91 Strong Revenue Growth Attractive EBITDA Trajectory 1. ITM figures translated at an EUR / USD rate of 1.14. 2026E reflects expected ITM revenue for 2026. Telix ASX disclosure September 21, 2026. The transaction with ITM is expected to close in FY2026 subject to Telix Shareholder approval, regulatory approvals, and other customary closing conditions. ITM Revenue ($M)(1) $198 $273 ~$300 2024A 2025A 2026E Manufacturing Growth ITM-11 (if FDA Approved) Future ITM Adjusted EBITDA ($M)(1) ~$50 ($12) 1H 26A ITM Cost Savings Program ITM Mfg. Growth Telix Synergies ITM-11 (if FDA Approved) 2028 Onwards ✓ Expected double-digit growth in ITM manufacturing revenue ✓ Expected high-margin commercial therapeutic revenues if ITM-11 is approved by FDA ✓ Strong gross margin in manufacturing (>40%) ✓ ITM cost saving program well advanced ✓ Positive EBITDA contribution from 2027 onwards ✓ $50M targeted synergies in the first two years Telix & ITM
Page 92
Final remarks Dr. Christian Behrenbruch Managing Director and Group CEO
Page 93
Transformational period of growth 1. Refers to revenue guidance of US $950M - $970M for FY2026 and $40M (Other Income), Telix ASX disclosure October 21, 2026. 2. Subject to close of transaction, the transaction with ITM is expected to close in FY2026 subject to Telix Shareholder approval, regulatory approvals, and other customary closing conditions. ~US $1B FY 2026E revenue and Other Income1 3 FDA approved imaging agents 22 countries Illuccix available 4 Therapeutic candidates in late-stage trials2 Scaling our commercial business Extending franchise leadership through product innovation, diversification and geographical expansion. Building on commercial success of three FDA approved products. Late-stage pipeline Advancing late-stage diagnostic and therapeutic assets towards patient access. Developing new targets and indications to fuel future growth. Best-in-class manufacturing & supply Expanding vertically integrated supply chain to support growth opportunities and extend competitive advantage – enabling growth at scale. A global radiopharma powerhouse 93
Page 94
Multiple growth drivers building on a strong 2026 revenue base Illustrative revenue bridge $USD ~$1B 2026 Illuccix / Gozellix Pixclara Zircaix BiPASS Ex-U.S. sales TMS revenues ITM-11 2027 Note: Illustrative only; growth drivers shown equally weighted and not indicative of relative contribution. No FY 2027 guidance implied. 1 Refers to revenue guidance of $950M - $970M for FY2026 and $40M (Other Income), Telix ASX disclosure October 21, 2026. 2. Subject to regulatory approvals. ITM assets subject to close of transaction, the transaction with ITM is expected to close in FY2026 subject to Telix Shareholder approval, regulatory approvals, and other customary closing conditions. 3. Potential launch in late 2027 or 2028, subject to FDA approval. Key data readouts in 2027: • TLX591-Tx futility analysis • TLX597-Tx OPTIMAL-PSMA • TLX090-Tx (Part A) • BiPASS 22+ countries 1 94 2 3 2